A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
The ceiling incremental cost-effectiveness ratio (ICER) beyond which interventions are no longer considered cost effective, reflecting the maximum value decision makers attach to health benefits. This may be stated in terms of cost per quality adjusted life year (QALY) gained.
See also:
Decision making unit (DMU)
Cost–benefit analysis
Cost-effective (healthcare economics)
Cost-effectiveness league table (healthcare economics)
Cost-minimisation analysis (CMA)
Cost consequences analysis (CCA)
Health Status Measure, Competitor analysis, Porter's 'Five Forces', Health Care prepayment plan (HCPP) (US) , Competitors, Interventions - clinical, Economic regulation, Global Health Observatory , Sensitivity analysis (pharmacoeconomics), British National Formulary (BNF), Payment by results (PBR) , Off-label use, European Association of Communications Agencies (EACA), Economic evaluation, Primary Care Trust (PCT),
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....